(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Investigate the Excellence of Professional flowerbeds: A Virtual Local escort - 2Spain and Catholic Church agree to compensate sex abuse victims
- 3Vote In favor of Your Favored Web based Dating Application
- 4Nikki Glaser returns as host of the 2026 Golden Globes: Everything the comedian has said about the upcoming awards show
- 5Cocaine, caffeine, painkillers consumed by sharks in Bahamas, study finds
- Creative Style: 10 Architects Reclassifying the Business
- Vote in favor of your #1 Sort of Convenience for a Family
- Architect Frank Gehry has died: See his most iconic buildings
- 10 Demonstrated Systems to Develop Your Internet based Business
- Dominating Monetary Administration: A Bit by bit Manual for Making an Individual Financial plan
- Norovirus is spreading earlier again this year, wastewater data shows
- Map shows more than 1,900 measles cases across U.S.
- This professional Santa's dream of spreading holiday cheer fuels stroke recovery
- Israel scales back use of top missile interceptors as Iran barrages persist
